Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00083408|
Recruitment Status : Completed
First Posted : May 25, 2004
Last Update Posted : July 5, 2010
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Pamidronate Drug: Thalidomide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve|
|Study Start Date :||March 1998|
|Study Completion Date :||May 2005|
- To evaluate the effectiveness of combination treatment with Thalidomide and Pamidronate in patients with refractory myeloma and poor hematopoietic stem cell reserve. Effectiveness will be based on the estimate of the objective response rate (CR + PR).
- To compare the effect of these agents on disease parameters, specifically on time to disease progression and overall survival.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00083408
|United States, Arkansas|
|University of Arkansas for Medical Sciences/MIRT|
|Little Rock, Arkansas, United States, 72205|
|Principal Investigator:||Athanasios Fassas, M.D.||University of Arkansas|